AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01671722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast sodium tablets 10mg
Study NCT01671722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Description: Montelukast sodium tablets 10mg
Study NCT01191905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose CRRT
Description: clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
Study NCT01191905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose CRRT
Description: clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
Study NCT04441736 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High flow nasal cannula
Description: Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
Study NCT04441736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
Study NCT01359956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 900 mg / m2 every 3 weeks
Study NCT01359956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 900 mg / m2 every 3 weeks
Study NCT01359956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine
Description: 100 mg / m2 every 3 weeks
Study NCT01359956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 5 M units every 3 weeks
Study NCT03499002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment
Description: Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
Study NCT02486211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100mg twice per day for 7 days at 0600 and 1200
Study NCT02486211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02673879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pericardiocentesis with Alteplase
Description: Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
Study NCT02673879 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Pericardiocentesis
Description: Conventional pericardiocentesis when indicated
Study NCT00686582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: 1x 10E8_TCID50
Study NCT00686582 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw Only
Study NCT02814435 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
Study NCT00797069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard nutritional product (medical food)
Description: once during crossover
Study NCT00989560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy
Description: patients receive best treatment and care with an additional endoscopy
Study NCT03119831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol-based Chlorhexidine Gluconate 0.12%
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study NCT03119831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol-free Chlorhexidine Gluconate 0.12%
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study NCT02814435 — intervention group
Intervention type: OTHER
Intervention: Computerised contrast sensitivity function test
Description: This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
Study NCT00797069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional product for diabetes (medical food)
Description: once during crossover
Study NCT00797069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes specific experimental nutritional product (medical food)
Description: once during crossover
Study NCT00987922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
Study NCT04417504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MobFood breakfast kit
Description: Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.
Study NCT04417504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control isocaloric breakfast
Description: White bread, butter and milk.
Study NCT02995330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
Study NCT02995330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cytoxan 50mg/kg IV on Days +3 and +4
Study NCT02995330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone cypionate
Description: testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
Study NCT01054976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
Study NCT05412537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI
Description: How to motivate people
Study NCT05412537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: consult as usual
Study NCT01098461 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: subcutaneous injection of albiglutide
Study NCT00710593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine for strains -6, -11, -16, and -18
Description: All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
Study NCT00525421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Description: Curcuminoids tablets 2000mg three times per day for 12 days
Study NCT00525421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03496116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Session
Description: Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
Study NCT01098461 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection of placebo to match albiglutide
Study NCT04428359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella Vaccine
Description: Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
Study NCT04428359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
Study NCT01309438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (normal renal function)
Description: One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
Study NCT01309438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (mild and moderate renal impairment)
Description: One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
Study NCT01309438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin (normal renal function)
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
Study NCT01309438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin (mild and moderate renal function)
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
Study NCT00411736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study medication, azithromycin or placebo
Description: Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
Study NCT00411736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin or placebo tablets
Description: Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
Study NCT04005950 — intervention group
Intervention type: DEVICE
Intervention: Scalpel Bougie technique
Description: ScalpelCric Set
Study NCT04005950 — intervention group
Intervention type: DEVICE
Intervention: modified Scalpel Bougie technique
Description: ScalpelCric Set plus speculum
Study NCT02862223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neoprinol
Study NCT00574431 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data Collection
Description: Collection of patient data before implementation of a nutritional management protocol
Study NCT00574431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional management protocol
Description: Collection of patient data after implementation of a nutritional management protocol
Study NCT02033772 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracoscopic surgery
Study NCT02662985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457 (secukinumab)
Description: Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections.
Study NCT02662985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AIN457 (secukinumab)
Description: Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections.
Study NCT02662985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
Study NCT00050791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
Study NCT00050791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet
Description: placebo injections
Study NCT03302208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin capsule 150 mg oral
Study NCT03302208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02484612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acute exercise
Study NCT04097171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will consume each diet for 14 days in a crossover design.
Study NCT03110601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Conventional SCS
Description: Conventional SCS Parameters
Study NCT03110601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test - Stimgenics SCS
Description: Stimgenics SCS Parameters
Study NCT02984774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
Study NCT02984774 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometrial sampling
Description: Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
Study NCT02984774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial sampling
Description: Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
Study NCT02984774 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheric blood sampling
Description: 4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
Study NCT02984774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheric blood sampling
Description: 4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
Study NCT02984774 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian tissue sampling
Description: 2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
Study NCT04171557 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bicycling
Description: Total bicycling is reported in categories of: (0 - reference), (>0 to \<60), (≤60 to >150), (≤150 to \< 300) and (≥300) minutes/week
Study NCT06044467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Study Part One
Description: Placebo Comparator
Study NCT06044467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Study Part Two
Description: Placebo Comparator
Study NCT04521530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate functional implant loading
Description: Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
Study NCT04521530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate non functional implant loading
Description: implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
Study NCT03262935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (vic-)trastuzumab duocarmazine
Description: Intravenous SYD985, Q3W
Study NCT03262935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice
Description: See drug label
Study NCT02520908 — intervention group
Intervention type: PROCEDURE
Intervention: HSCT
Description: Hematopoietic stem cell transplantation
Study NCT02520908 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Study NCT00557206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Docetaxel
Description: Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days.
Study NCT00373386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: Growth Hormone treatment
Study NCT04414995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol injection and Ibuprofen injection
Description: Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
Study NCT04414995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol injection and normal saline
Description: Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
Study NCT04414995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Injection and normal saline
Description: Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
Study NCT04280497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.
Study NCT04280497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.
Study NCT03119831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C31G
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study NCT02767843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous negative external pressure (cNEP)
Description: soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
Study NCT02024412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialotetrahexosylganglioside Sodium
Description: it is a component extract from pig's brain,shenjie is the brand name
Study NCT02024412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline of the same appearance as monosialotetrahexosylganglioside Sodium
Study NCT02692196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Study NCT02692196 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Study NCT02403544 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT
Description: IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
Study NCT02403544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
Study NCT02403544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
Study NCT03852030 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text or email message
Description: Text or email messages sent to research participants
Study NCT03852030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text or email message
Description: Text or email messages sent to research participants
Study NCT02481414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepCan
Description: 50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
Study NCT02481414 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candin®
Description: 0.3 mL Candin® per dose administered intradermally in the extremities
Study NCT03825627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total).